Liang Wen Xiuwen Zou Yiwen Chen Xueli Bai Tingbo Liang
10.3389/fimmu.2020.02076
Front Immunol
2020 Aug 21;11:2076.
pd-1 inhibitor sintilimab autoimmune diabetes hepatocellular carcinoma immune related adverse event plasma glucose
CC BY
https://pubmed.ncbi.nlm.nih.gov/32973816/
Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Agents, Immunological / adverse effects Carcinoma, Hepatocellular / drug therapy Diabetes Mellitus, Type 1 / diagnosis Immune Checkpoint Inhibitors / adverse effects Immunotherapy / methods Liver Neoplasms / drug therapy
Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Agents, Immunological / adverse effects Carcinoma, Hepatocellular / drug therapy Diabetes Mellitus, Type 1 / diagnosis Immune Checkpoint Inhibitors / adverse effects Immunotherapy / methods Liver Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Autoantibodies / blood China Diabetes Mellitus, Type 1 / etiology Glucose / metabolism Humans Immune Checkpoint Inhibitors / therapeutic use Insulin / administration & dosage Male Middle Aged Programmed Cell Death 1 Receptor / immunology Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Autoantibodies Immune Checkpoint Inhibitors Insulin PDCD1 protein, human Programmed Cell Death 1 Receptor sintilimab Glucose
PMC7472830
32973816
Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
2020